Reported impact
Business outcome
Moderna accelerated internal work across major functions, created hundreds of valuable GPT use cases, improved clinical and legal throughput, and strengthened its ability to launch many new therapies with a comparatively lean workforce.
- Productivity Improvement
- Risk Reduction
- Speed to Market
Solution
Moderna paired organization-wide change management with ChatGPT Enterprise to make generative AI part of every function. The rollout started with mChat, an internal chatbot built on OpenAI’s API that reached more than 80% employee adoption and prepared the company for ChatGPT Enterprise. Moderna then drove a broader transformation program with training, AI learning companions, prompt contests, executive sponsorship, local office hours, and a cohort of internal Generative AI Champions. Once employees could create their own GPTs, hundreds of use cases appeared across the business. One notable example is Dose ID, a GPT that uses advanced data analysis to review clinical data, analyze vaccine-dose options, cite sources, generate charts, and help study teams make safer, faster clinical decisions. Additional GPTs summarize contracts, answer policy questions, and translate biotech language for investor communications. Across the company, AI acts as an amplifier for a few thousand people to work more like an organization many times their size while keeping humans in charge of final judgment.
Data flow
Internal business, clinical, legal, and communications tasks flow into ChatGPT Enterprise and Moderna’s custom GPTs. mChat and enterprise workspaces collect prompts and patterns, while Dose ID processes large clinical datasets and returns cited rationales and visualizations for human-led study review.